Open access

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

Eugenio Galli D. Mannina Alessandro Corrente C. de Philippis Ilaria Pansini M. Viscovo S. Hohaus P. Chiusolo F. Sorà S. Bramanti Simona Sica

Aug 2026 · European Journal of Haematology · Vol 117, pp. 1630 - 1636 · 1 citation · 16 references

Medicine

TL;DR

The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.

Abstract

Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing on treatment‐related toxicities.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Oct 2026

Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis

Immune‐related adverse events (irAEs) frequently occur during combination immune checkpoint inhibition. However, their prognostic impact may vary according to organ involvement and severity. In this study, we exploratorily evaluated whether severe non‐endocrine irAEs represent a temporally distinct and prognostically u...

Y. Tasaki, Kazumasa Sato, S. Hamamoto et al. · Cancer Medicine · 0 citations

Clinical trial Open access Oct 2026

Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012

The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biomarkers and clinical outcomes were assessed.

Andrew B. Nixon, Danielle M. Enserro, D. Bender et al. · Cancer · 0 citations

Open access Oct 2026

Development and Validation of the JIKEI‐YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI‐Based Doublet Therapy

Metastatic castration‐sensitive prostate cancer (mCSPC) is a heterogeneous disease with variable clinical outcomes despite advances in androgen receptor signaling inhibitor (ARSI)‐based therapy. We aimed to develop and externally validate a prognostic model for predicting progression to castration‐resistant prostate ca...

F. Urabe, Yudai Ishiyama, Wataru Fukuokaya et al. · International journal of uro... · 1 citation

Open access Sep 2026

Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study

Inotuzumab (InO)‐based frontline regimens have significantly improved the survival of older patients with Philadelphia‐negative (Ph–) B‐cell acute lymphoblastic leukemia (B‐ALL). Yet, outcome after relapse is not reported for this population.

Perrine Moyer, T. Leguay, M. Jullien et al. · Cancer · 0 citations

Open access Oct 2026

Does PD‐L1 Combined Positive Score Have Prognostic Value in Hypopharyngeal Squamous Cell Carcinoma? A Retrospective Cohort Study

The aim of this study was to determine whether pretreatment PD‐L1 CPS is prognostically associated with survival in patients with HPSCC treated nonsurgically and without immunotherapy, and to assess overall survival (OS) in actively treated patients without distant metastases according to CPS < 1 versus CPS ≥ 1.

Saša Jakovljević, V. Djordjevic, Nada Tomanović et al. · Laryngoscope Investigative O... · 0 citations

Open access Oct 2026

Eosinophil Dynamics May Help Differentiate Immune‐Related From TKI‐Related Adverse Events During IO–TKI Therapy for Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors (IO–TKI) is a key treatment option for metastatic renal cell carcinoma (mRCC), but distinguishing immune‐related adverse events (irAEs) from TKI‐related adverse events (TKI‐AEs) is challenging because of overlapping clinical features....

Misato Tomita, Y. Tasaki, S. Hamamoto et al. · Cancer Medicine · 0 citations